Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old
• People whose lung cancer has been confirmed as small cell lung cancer through a tissue or cell sample test
• People who have at least one tumour that can be measured on a scan, according to standard medical criteria
• People whose cancer has come back or gotten worse within 6 months of completing a first-line chemotherapy or combined chemotherapy and radiation treatment that included platinum-based drugs
• People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (ECOG score of 0–2) (confirm with trial site)
• People whose life expectancy is estimated to be more than 3 months
• People who have largely recovered from the side effects of any previous cancer treatments, with only mild or no lasting effects remaining
• People whose major organs — including bone marrow, liver, kidneys, and blood clotting system — are functioning within acceptable levels on blood tests, and whose urine protein levels are within acceptable limits

Who may not be able to join:

• People diagnosed with a different but related type of lung cancer, such as large cell neuroendocrine lung carcinoma or combined small cell lung carcinoma
• People with cancer that has spread to the brain or spinal cord that is not well controlled, or that requires an increased dose of steroid medication (those with well-controlled brain metastases may still be considered)
• People who have fluid build-up around the lungs, abdomen, or heart that has not been controlled by drainage or other treatments in the 2 weeks before starting the study
• People who have been diagnosed with another cancer in the past 5 years, except for certain fully treated skin cancers or very early-stage cancers confined to one area
• People who have previously been treated with irinotecan, liposomal irinotecan, or certain anti-blood-vessel-growth drugs such as anlotinib or bevacizumab
• People taking certain medications that strongly affect how the body processes drugs (known as strong CYP3A4 inducers or inhibitors, or strong UGT1A1 inhibitors) within a short period before starting the trial (confirm timing with trial site)
• People who have received any other anti-cancer treatment — including radiation, chemotherapy, or immunotherapy — within 4 weeks before starting the trial
• People with serious uncontrolled heart conditions, such as unstable chest pain, recent heart attack, heart failure, or severe irregular heartbeat
• People who have had a serious lung disease — such as scarring of the lung tissue or severe radiation-related lung inflammation requiring steroids — within the 6 months before joining
• People who have had a blood clot in a vein or artery — such as a stroke, mini-stroke, deep vein clot, or pulmonary embolism — within the 6 months before joining
• People who have had bleeding problems or signs of bleeding within 3 months before screening, including stomach or bowel bleeding or certain blood vessel conditions
• People who have had a major surgical procedure within 4 weeks before starting the trial, or who are expected to need major surgery during the study
• People with wounds, ulcers, or broken bones that have not healed
• People whose scans show that the tumour is growing close to or involving major blood vessels in a way that could cause serious bleeding
• People with an active, uncontrolled infection (bacterial, viral, or fungal) that requires treatment
• People with active hepatitis B, hepatitis C, or HIV infection
• People with a known allergy or intolerance to the study drugs or their ingredients
• People with significant ongoing digestive or bowel problems, including liver disorders, bleeding, inflammation, blockage, or more than mild diarrhoea
• People who are pregnant or breastfeeding
• People considered unsuitable for the trial for any other reason, based on the treating doctor's judgement

Important: Always verify eligibility with the trial site directly before applying.